Helix Biopharma Corp. to Present at RHK Capital Conference in New York
July 24 2019 - 5:05PM
Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an
immuno-oncology company developing innovative drug candidates for
the prevention and treatment of cancer, announces that it will be
presenting at the RHK Capital 2019 Disruptive Growth &
Healthcare Conference (www.disruptnyc.com).
RHK Capital’s Disruptive Growth & Healthcare
Conference showcases life science companies that focus on solutions
for unmet medical needs and growth companies with disruptive
technologies and business models. The 2019 Disruptive Growth
& Healthcare Conference will be held on Wednesday, September
4th and Thursday, September 5th in New York.
“We are pleased to present Helix at this venue,”
said Dr. Heman Chao, Helix’s Chief Executive Officer. “As
part of the Company’s objective to increase awareness of the
Company’s novel DOS47 tumor microenvironment platform, the Company
will be actively participating in select conferences and non-deal
roadshows during the second half of calendar 2019”.
About Helix BioPharma Corp.
Helix BioPharma Corp. is an immuno-oncology
company specializing in the field of cancer therapy. The company is
actively developing innovative products for the prevention and
treatment of cancer based on its proprietary technologies. Helix’s
product development initiatives include its novel L-DOS47 new drug
candidate and Chimeric Antigen Receptor (“CAR”) based cell
therapies. Helix is currently listed on the TSX under the symbol
“HBP”.
Investor Relations
Helix BioPharma Corp.9120 Leslie Street, Suite
205Richmond Hill, Ontario, L4B 3J9Tel: 905-841-2300Email:
ir@helixbiopharma.com
Cautionary Statements
This news release may contain forward-looking
statements with respect to Helix, its operations, strategy,
financial performance and condition, including its activities
relating to its drug development program, any anticipated timelines
for the commencement or completion of certain activities such as
raising sufficient capital, merger and acquisition activity,
listing on a U.S. exchange and other information in future periods.
These statements generally can be identified by use of
forward-looking words such as “ambitions”, “potentially
breakthrough”, “should”, “may”, “will”, “expect”, “estimate”,
“anticipate”, “intends”, “believe” or “continue” or the negative
thereof or similar variations. The actual results and performance
of discussed herein could differ materially from those expressed or
implied by such statements. Such statements are qualified in their
entirety by the inherent risks and uncertainties surrounding future
expectations, including: (i) Helix’s ability to operate as a going
concern being dependent mainly on securing sufficient additional
financing in order to fund its ongoing research and development and
other operating activities; (ii) the generally inherent uncertainty
involved in scientific research and drug development and those
specific to Helix’s pre-clinical and clinical development programs
(DOS47, L-DOS47, V-DOS47 and CAR-T); (iii) that any transactions
contemplated herein are completed; and (iv) those risks and
uncertainties affecting Helix as more fully described in Helix’s
most recent Annual Information Form, which is available at
www.sedar.com (together, the “Helix Risk Factors”). Certain
material factors and assumptions are applied in making the
forward-looking statements, including, without limitation, that
sufficient financing will be obtained in a timely manner to allow
Helix to continue operations and implement its clinical trials in
the manner and on the timelines anticipated and that the Helix Risk
Factors will not cause Helix’s actual results or events to differ
materially from the forward-looking statements. These cautionary
statements qualify all such forward-looking statements.
Forward-looking statements and information are
based on the beliefs, assumptions, opinions, plans and expectations
of Helix’s management on the date of this news release, and the
Company does not assume any obligation to update any
forward-looking statement or information should those beliefs,
assumptions, opinions, plans or expectations, or other
circumstances change, except as required by law.
Huttig Building Products (NASDAQ:HBP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Huttig Building Products (NASDAQ:HBP)
Historical Stock Chart
From Sep 2023 to Sep 2024